BACKGROUND: Many regimens of @entity136 - @entity900 chemotherapy have proven activity in @entity1 with advanced @entity1149 ( @entity1149 ). However, the optimal dose and schedule still have to be established. @entity1 AND METHODS: We conducted a phase II study with administration of @entity900 50 mg/m(2) on days 1 and 8 and @entity136 800 mg/m(2) on days 2, 9 and 15. This schedule was selected to optimise the synergism between the two drugs and reduce @entity137 due to high dose @entity900 . RESULTS: Thirty-six chemo-naive @entity1 with stage IIIA, IIIB or IV @entity1149 entered the study (26 @entity1 , 10 @entity1 ; median age 58 years, range 29-74). Twenty @entity1 achieved a partial response: 7 out of 10 stage IIIA @entity1 , 7 out of 13 stage IIIB @entity1 and 6 out of 13 stage IV @entity1 . On intent-to-treat basis, the overall response rate (RR) was 58% (95% confidence interval, 42-74%). Ninety percent of stage IIIA @entity1 and 46% of stage IIIB @entity1 received adjuvant surgery or radiotherapy. Overall median duration of response was 28 weeks (range 6-147 weeks). For stage IIIA, IIIB and IV @entity1 , these numbers were 91, 13 and 23 weeks, respectively. One-year survival was 49% with 90%, 23% and 42% for stage IIIA, IIIB and IV @entity1 , respectively. The main @entity137 was myelosuppression. WHO grades 3 and 4 @entity1431 occurred in 67% of @entity1 , whereas 61% experienced grade 3 or 4 @entity882 . Although hematological @entity137 was clinically tolerable, it frequently led to omission of @entity136 administration on day 15. The incidence of @entity1503 was very low. CONCLUSION: This regimen of @entity900 on days 1 and 8 and @entity136 on days 2, 9 and 15 induced a high RR in @entity1 with advanced NCSLC. Frequent omission of @entity136 day 15 is a limitation of this schedule. This should be an important factor in a practical approach to decide on the most optimal schedule of the @entity900 plus @entity136 combination.

Combination of XXXX and @entity900 for advanced @entity1149 : a phase II study with emphasis on scheduling.

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'PATIENTS', 'men'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1503 :: ('MESH:D006402', 'Disease') :: ['non-hematological toxicity'] @entity1431 :: ('MESH:D007970', 'Disease') :: ['leukopenia'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine']
@entity136 :: (MESH:C056507,Chemical) :: ['gemcitabine']
